- Monocl welcomes a range of global leading pharmaceutical companies, scientific instrument manufacturers and CROs to its rapidly growing customer base.
- The company closed its largest deal to date in Q1 2018 with a non-disclosed top 5 Big Pharma.
- To further fuel its rapid growth, Monocl will initiate a Series A funding round during Q2 2018.
Björn Carlsson, CEO of Monocl, sums it up: “The first quarter of 2018 was our strongest to date. This is very exciting since we beat our previous all-time high from the final quarter of 2017. The fact that our performance is exceeding our highly set expectations really validates that we are creating a ton of value for our customers and that we are on to something big with our groundbreaking approach to stakeholder mapping and stakeholder engagement”.
Monocl will now take the next step in its strategic growth plan and initiate a Series A funding round during the second quarter. Geographic expansions have already been made to strategic locations in the US, UK and Japan. The proceeds will be used to further fuel the company’s growth in the United States, Europe and Asia. Monocl will also add new groundbreaking capabilities and third-party integrations to its cloud-hosted stakeholder platform to further address customer requests.